In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Stereotactic Radiosurgery for Skull Base Meningiomas: 20-year Long-term Outcomes with Volumetric Analysis

    Final Number:
    143

    Authors:
    Mohana Rao Patibandla MBBS MCh; Cheng-Chia Lee; Gokul C Addagada MBBS; Jason P. Sheehan MD PhD FACS

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: Stereotactic radiosurgery (SRS) has become an integral part in the treatment of benign intracranial tumors, including meningiomas. Previous studies have typically used single diameter measurements when reporting outcomes, which can yield misleading results. The authors describe the use of SRS in the treatment of WHO grade I PFMs and correlate volumetric analysis with long-term outcomes.

    Methods: This study is a retrospective analysis of a prospectively maintained IRB-approved database. Inclusion criteria were a diagnosis of WHO grade I SM treated with single-session SRS and has a minimum of 3 follow-up MRI studies available. Volumetric analysis was performed on the radiosurgical scan and each subsequently available follow-up scan by using slice-by-slice area calculations of the meningioma and numerical integration with the trapezoid rule.

    Results: The final cohort consisted of 377 patients, 76.4% (288) of whom were female, with a median age of 57 years (12-88 years). SRS was the primary treatment for 49.3% (186) of the patients, whereas 38.7% (146) had 1 resection before SRS treatment and 12% (45) had 2 or more resections before SRS. Tumor characteristics included a median volume of 4.7 cm3 (0.1-54.8 cm3) at treatment with a median margin dose of 14 Gy (6-35 Gy). The median clinical and imaging follow-ups were 79.5 (15-328) and 72 (7-298) months, respectively. The actuarial progression-free survival rates at 5, 10, 15, and 20 years were 98.6%, 94.4%, 84.6%, and 77.6%, respectively. Overall post SRS new neurological deterioration 17.8% (n=67). The clinical deterioration is related to the tumor progression (p< 0.001, 95% CI: 2.460-18.559, and OR: 6.756). Volumetric analysis demonstrated that a change in tumor volume at 3 years after SRS reliably predicted a volumetric change and tumor control at 5 years (R2 = 0.62) with a p < 0.001 and at 10 years (R2 = 0.062) with a p = 0.002.

    Conclusions: SRS, as either upfront or adjuvant treatment, is a durable therapeutic option for WHO grade I SMs, with high tumor control and a low incidence of post-SRS neurological deficits. Lesion volumetric response at the short-term follow-up of 3 years is predictive of the long-term response at 5 and 10 years.

    Patient Care: Skull base meningioma resection involves a lot of morbidity and mortality which can be reduced by using the SRS which has a low rate of complications with a high rate of PFS.

    Learning Objectives: SRS is an alternative method for the treatment of benign meningiomas both as an upfront and an adjunctive modality.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy